{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T13:21:49Z","timestamp":1772976109724,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006545","name":"National Institute on Minority Health and Health Disparities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006545","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.clml.2025.09.009","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T16:43:59Z","timestamp":1757781839000},"page":"e103-e109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Curability Potential of Low-Grade Follicular Lymphoma"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9234-7893","authenticated-orcid":false,"given":"F.","family":"Cabanillas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.G.","family":"Conde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Abreu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.B.","family":"Hagemeister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.clml.2025.09.009_bib0001","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.clml.2016.08.011","article-title":"Indolent lymphomas that present with clinically aggressive features: a subset of low-grade lymphomas with a behavior inconsistent with the histologic diagnosis","volume":"16","author":"Cabanillas","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"23","key":"10.1016\/j.clml.2025.09.009_bib0002","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1182\/blood-2015-11-632745","article-title":"Is watch and wait still acceptable for patients with low-grade follicular lymphoma?","volume":"127","author":"Armitage","year":"2016","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2025.09.009_bib0003","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s00277-016-2668-0","article-title":"Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin's lymphoma: evidence from a multicenter, retrospective study","volume":"95","author":"Mondello","year":"2016","journal-title":"Ann Hematol"},{"issue":"10","key":"10.1016\/j.clml.2025.09.009_bib0004","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1200\/JCO.2005.03.3696","article-title":"Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center","volume":"24","author":"Liu","year":"2006","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.clml.2025.09.009_bib0005","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2025.09.009_bib0006","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1182\/blood-2013-03-491514","article-title":"Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience","volume":"122","author":"Tan","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2025.09.009_bib0007","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/bjh.14541","article-title":"High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: results of a randomized study","volume":"177","author":"Nastoupil","year":"2017","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2025.09.009_bib0008","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1200\/JCO.2012.41.7527","article-title":"Curability of advanced indolent or low-grade follicular lymphomas: time for a new paradigm?","volume":"31","author":"Cabanillas","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2025.09.009_bib0009","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1080\/10428194.2021.1971216","article-title":"A randomized phase II study comparing consolidation with a single dose of (90)Y ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results","volume":"63","author":"Lopez-Guillermo","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.clml.2025.09.009_bib0010","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-020-00340-z","article-title":"Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups","volume":"10","author":"Batlevi","year":"2020","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.clml.2025.09.009_bib0011","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2025.09.009_bib0012","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/annonc\/mdn657","article-title":"The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL)","volume":"20","author":"Noy","year":"2009","journal-title":"Ann Oncol"},{"issue":"27","key":"10.1016\/j.clml.2025.09.009_bib0013","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2025.09.009_bib0014","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1200\/JCO.1994.12.3.575","article-title":"Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma","volume":"12","author":"McLaughlin","year":"1994","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2025.09.009_bib0015","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1182\/blood.V79.4.1024.bloodjournal7941024","article-title":"Clinical, biologic, and histologic features of late relapses in diffuse large cell lymphoma","volume":"79","author":"Cabanillas","year":"1992","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2025.09.009_bib0016","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/bjh.16973","article-title":"The road to a cure: are some patients there yet? Commentary on the 2020 UK guidelines for follicular lymphoma","volume":"191","author":"Trotman","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2025.09.009_bib0017","series-title":"Presented at: 17th International Conference on Malignant Lymphoma (ICML); June 13\u201317, 2023","article-title":"15-year follow-up of SWOG-S0016: achieving a functional cure in a subset of patients with follicular lymphoma","author":"Shadman","year":"2023"},{"issue":"2","key":"10.1016\/j.clml.2025.09.009_bib0018","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/bjh.18640","article-title":"Long-term follow-up demonstrates curative potential of autologous stem cell transplantation for relapsed follicular lymphoma","volume":"201","author":"Puckrin","year":"2023","journal-title":"Br J Haematol"},{"issue":"18","key":"10.1016\/j.clml.2025.09.009_bib0019","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1200\/JCO.2006.09.8327","article-title":"Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up","volume":"25","author":"Rohatiner","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.09.009_bib0020","series-title":"Presented at: 65th American Society of Hematology (ASH) Annual Meeting and Exposition; December 9-12, 2023","article-title":"Axicabtagene ciloleucel in patients with relapsed\/refractory indolent non-Hodgkin lymphoma: 4-year follow-up from the phase 2 ZUMA-5 trial","author":"Neelapu","year":"2023"},{"issue":"2","key":"10.1016\/j.clml.2025.09.009_bib0021","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3324\/haematol.2019.235598","article-title":"Clinicopathological and genetic features of limited-stage diffuse large B-cell lymphoma with late relapse: targeted sequencing analysis of gene alterations in the initial and late relapsed tumors","volume":"106","author":"Suzuki","year":"2021","journal-title":"Haematologica"},{"issue":"25","key":"10.1016\/j.clml.2025.09.009_bib0022","doi-asserted-by":"crossref","first-page":"4164","DOI":"10.1200\/JCO.23.00570","article-title":"Relapse timing is associated with distinct evolutionary dynamics in diffuse large B-cell lymphoma","volume":"41","author":"Hilton","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042144?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042144?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T02:49:56Z","timestamp":1772938196000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025042144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2152265025042144"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.09.009","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Curability Potential of Low-Grade Follicular Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}